UK Markets closed

ARECOR ANNOUNCES AN EXCLUSIVE FORMULATION STUDY COLLABORATION WITH A LEADING GLOBAL MEDICAL PRODUCTS COMPANY TO DEVELOP A STABLE READY TO ADMINISTER PRODUCT

·2-min read

Arecor Therapeutics plc
(“Arecor” or the “Group”)

ARECOR ANNOUNCES AN EXCLUSIVE FORMULATION STUDY COLLABORATION WITH
A LEADING GLOBAL MEDICAL PRODUCTS COMPANY TO DEVELOP A STABLE READY TO ADMINISTER PRODUCT

Cambridge, UK, 1 November 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration with a leading global medical products company.

Under the terms of the agreement, Arecor will use its proprietary formulation technology platform, Arestat™, to develop a differentiated, stable, liquid drug product, for intravenous administration in two concentrations, that is Ready-to-Administer (“RTA”). The new liquid formulation of the product supports safe medication practices and operational efficiency by eliminating the need for reconstitution. The partner will fund the development work and has the option to acquire the rights to the new proprietary formulation and associated Intellectual Property under a technology licensing model to further develop and commercialise the product.

Sarah Howell, Chief Executive Officer of Arecor, said: "We are very pleased to announce this new partnership today, our fourth in the past six months, showcasing our commercial strategy to drive growth through our portfolio of collaborations across leading pharmaceutical, medical products and biotech companies. This collaboration further demonstrates the strength of our proprietary technology platform, Arestat in developing ready-to-administer (RTA) medicines, which are becoming increasingly important to enable fast, safe and effective treatment of patients.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR)

-ENDS-

For more information, please contact:

Arecor Therapeutics plc

www.arecor.com

Dr Sarah Howell, Chief Executive Officer

Tel: +44 (0) 1223 426060
Email: info@arecor.com

Susan Lowther, Chief Financial Officer

Tel: +44 (0) 1223 426060
Email: info@arecor.com

Mo Noonan, Communications

Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com

Panmure Gordon (UK) Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)

Tel: +44 (0) 20 7886 2500

Consilium Strategic Communications

Chris Gardner, David Daley, Angela Gray

Tel: +44 (0) 20 3709 5700
Email: arecor@consilium-comms.com

Notes to Editors

About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting